Cellectis (CLLS) Tops Q4 EPS by 19c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Cellectis (CLLS) Tops Q4 EPS by 19c

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results

March 4, 2020 4:30 PM EST

Enrollment ongoing in Phase 1 dose-escalation trials AMELI-01 in r/r AML patients, BALLI-01 in r/r B-ALL patients and MELANI-01 in r/r MM patients Expanding collaboration with Servier on UCART19 products, including ALLO-501 and ALLO-501A sublicensed to Allogene Entered into new research collaboration with Iovance Biotherapeutics for use of TALEN® technology to develop gene-edited TIL for cancer therapeutics Construction of in-house manufacturing sites on track in Paris, France and Raleigh, North Carolina Cash... More